Neoplasia: An International Journal for Oncology Research (Apr 2015)

The Differential Effects of Anti-Diabetic Thiazolidinedione on Prostate Cancer Progression Are Linked to the TR4 Nuclear Receptor Expression Status

  • Shin-Jen Lin,
  • Chang-Yi Lin,
  • Dong-Rong Yang,
  • Kouji Izumi,
  • Emily Yan,
  • Xiaodan Niu,
  • Hong-Chiang Chang,
  • Hiroshi Miyamoto,
  • Nancy Wang,
  • Gonghui Li,
  • Chawnshang Chang

DOI
https://doi.org/10.1016/j.neo.2015.02.005
Journal volume & issue
Vol. 17, no. 4
pp. 339 – 347

Abstract

Read online

The insulin sensitizers, thiazolidinediones (TZDs), have been used as anti-diabetic drugs since the discovery of their ability to alter insulin resistance through transactivation of peroxisome proliferator-activated receptors (PPARs). However, their side effects in hepatitis, cardiovascular diseases, and bladder cancer resulted in some selling restrictions in the USA and Europe. Here, we found that the potential impact of TZDs on the prostate cancer (PCa) progression might be linked to the TR4 nuclear receptor expression. Clinical surveys found that 9% of PCa patients had one allele TR4 deletion in their tumors. TZD increased cell growth and invasion in PCa cells when TR4 was knocked down. In contrast, TZD decreased PCa progression in PCa cells with wild type TR4. Mechanism dissection found that the Harvey Rat Sarcoma (HRAS) oncogene increased on TZD treatment of the TR4 knocked-down CWR22Rv1 and C4-2 cells, and interruption with HRAS inhibitor resulted in reversal of TZD-induced PCa progression. Together, these results suggest that TZD treatment may promote PCa progression depending on the TR4 expression status that may be clinically relevant since extra caution may be needed for those diabetic PCa patients receiving TZD treatment who have one allele TR4 deletion.